Image-based quantification of benzoporphyrin derivative uptake, localization, and photobleaching in 3D tumor models, for optimization of PDT parameters

Theranostics

Volumn 2, Issue 9, 2012, Pages 827-839

  Glidden, Michael D ^a,b   Celli, Jonathan P ^a,b   Massodi, Iqbal ^a   Rizvi, Imran ^a   Pogue, Brian W ^c   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

BPD; Fractionation; In vitro 3D tumor model; PDT; Photodynamic therapy; Photosensitizer imaging; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PHOTOSENSITIZING AGENT; VERTEPORFIN;

ARTICLE; BLEACHING; CELL KILLING; CONTROLLED STUDY; DOSIMETRY; DRUG CYTOTOXICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; PHOTODYNAMIC THERAPY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR MODEL;

EID: 84866053007     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4334     Document Type: Article

References (34)

1. Kostron H, Obwegeser A, Jakober R. Photodynamic therapy in neurosurgery: a review. Journal of Photochemistry and Photobiology B: Biology. 1996; 36: 157-68.
2. Pass HI. Photodynamic Therapy in Oncology: Mechanisms and Clinical Use. Journal of the National Cancer Institute. 1993; 85: 443-56.
3. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3: 380-7.
4. Hasan T, Parrish JA. Photodynamic therapy of cancer; 4th ed. Williams & Wilkins; 1997.
5. MacCormack MA. Photodynamic Therapy in Dermatology: An Update on Applications and Outcomes. Seminars in Cutaneous Medicine and Surgery. 2008; 27: 52-62.
6. Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, et al. Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization. Chemical Reviews. 2010; 110: 2795-838.
7. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology. 2006; 7: 392-401.
8. Celli J, Rizvi I, Evans C, Abu Yousif A, Hasan T. Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model. Journal of biomedical optics. 2010; 15: 051603.
9. Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer research. 2010; 70: 9319-28.
10. Wilson BC, Patterson MS, Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a New paradigm. Lasers Med Sci. 1997; 12: 182-99.
11. Wang KK, Mitra S, Foster TH. A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy. Med Phys. 2007; 34: 282-93.
12. Xue J, Li C, Liu H, Wei J, Chen N, Huang J. Optimal light dose and drug dosage in the photodynamic treatment using PHOTOCYANINE. Photodiagnosis Photodyn Ther. 2011; 8: 267-74.
13. Iinuma S, Schomacker KT, Wagnieres G, Rajadhyaksha M, Bamberg M. In vivo fluence rate and fractionation effects on tumor response and photobleaching: Photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer research. 1999; 59: 6164-70.
14. Pogue BW, Sheng C, Benevides J, Forcione D, Puricelli B, Nishioka N, et al. Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus. J Biomed Opt. 2008; 13: 034009.
15. Lin C-W, Shulok JR, Wong Y-K, Schanbacher CF, Cincotta L, Foley JW. Photosensitization, Uptake, and Retention of Phenoxazine Nile Blue Derivatives in Human Bladder Carcinoma Cells. Cancer research. 1991; 51: 1109-16.
16. Miller GG, Brown K, Moore RB, McPhee MS, Diwu ZJ, Liu J, et al. Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study. Photochem Photobiol. 1995; 61: 632-8.
17. Jarvi MT, Niedre MJ, Patterson MS, Wilson BC. Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: current status, challenges and future prospects. Photochem Photobiol. 2006; 82: 1198-210.
18. Curnow A, Haller JC, Bown SG. Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon: Comparison of continuous and fractionated light regimes. Journal of Photochemistry and Photobiology B: Biology. 2000; 58: 149-55.
19. van Geel IPJ, Oppelaar H, Marijnissen JPA, Stewart FA. Influence of Fractionation and Fluence Rate in Photodynamic Therapy with Photofrin or mTHPC. Radiation Research. 1996; 145: 602-9.
20. Ascencio M, Estevez JP, Delemer M, Farine MO, Collinet P, Mordon S. Comparison of continuous and fractionated illumination during hexaminolaevulinate-photodynamic therapy. Photodiagnosis and Photodynamic Therapy. 2008; 5: 210-6.
21. de Bruijn HS, de Haas ERM, Hebeda KM, van der Ploeg - van den Heuvel A, Sterenborg HJCM, Neumann HAM, et al. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal mouse skin. Photochemical & Photobiological Sciences. 2007; 6: 1325-31.
22. Müller S, Walt H, Dobler-Girdziunaite D, Fiedler D, Haller U. Enhanced photodynamic effects using fractionated laser light. Journal of Photochemistry and Photobiology B: Biology. 1998; 42: 67-70.
23. Babilas P, Schacht V, Liebsch G, Wolfbeis OS, Landthaler M, Szeimies RM, et al. Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo. Br J Cancer. 2003; 88: 1462-9.
24. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL. Oxygen consumption and diffusion effects in photodynamic therapy. Radiation Research. 1991; 126: 296-303.
25. Pogue BW, Hasan T. A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiation Research. 1997; 147: 551-9.
26. van den Boogert J, van Staveren HJ, de Bruin RW, Siersema PD, van Hillegersberg R. Fractionated illumination for oesophageal ALA-PDT: effect on blood flow and PpIX formation. Lasers Med Sci. 2001; 16: 16-25.
27. Celli J, Solban N, Liang A, Pereira S, Hasan T. Verteporfin-Based Photodynamic Therapy Overcomes Gemcitabine Insensitivity in a Panel of Pancreatic Cancer Cell Lines. Lasers in surgery and medicine. 2011; 43: 565-74.
28. Evans CL, Abu-Yousif AO, Park YJ, Klein OJ, Celli JP, Rizvi I, et al. Killing Hypoxic Cell Populations in a 3D Tumor Model with EtNBS-PDT. PLoS ONE. 2011; 6: e23434.
29. Celli J, Blanden A, Rizvi I, Abu-Yousif AO, Spring BQ, Hasan T. Biologically relevant 3D tumor arrays: imaging-based methods for quantification of reproducible growth and analysis of treatment response. Proceedings of SPIE. 2011;: 7886.
30. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring-A (BPD-MA). Photochemistry and photobiology. 1994; 59: 328-35.
31. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Meth. 2007; 4: 359-65.
32. Abramoff M, Magelhaes P, Ram S. Image processing with ImageJ. Biophotonics International. 2004; 11: 36-42.
33. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochemistry and Photobiology. 1993; 57: 1000-6.
34. Nichols MG, Foster TH. Oxygen diffusion and reaction-kinetics in the photodynamic therapy of multicell tumor spheroids. Physics in Medicine and Biology. 1994; 39: 2161-81.